#Ferroptosis #ResistantCancer #LysosomalIron #CD44 #Pancreas #Sarcoma
Aggressive solid tumors, such as pancreatic cancer or certain sarcomas,
have a remarkable ability to evade treatment. These cancers often harbor a
subset of cells known as
“drug-tolerant persister cells” (DTPs), capable of
surviving conventional therapies. A Franco-international team has recently
uncovered an unsuspected vulnerability: their
dependency on iron—specifically,
iron stored within lysosomes.
A study led by Raphaël Rodriguez, published in Nature in June
2025, reveals that targeted activation of lysosomal iron triggers ferroptosis,
a form of cell death driven by lipid peroxidation. This research paves the way
for a novel therapeutic strategy—one that targets not the tumor’s genetics, but
its cellular state and iron metabolism.
Cell death as a therapeutic tool
Ferroptosis is mechanistically distinct from apoptosis. It results from
the uncontrolled buildup of oxidized lipids within cell membranes. Iron is a
potent catalyst for this chain reaction. In tumors, certain cells accumulate
iron in their lysosomes—organelles responsible for cellular degradation—which
paradoxically makes them vulnerable to oxidation.
The authors demonstrate that liproxstatin-1, a ferroptosis inhibitor,
works by neutralizing iron in lysosomes. Conversely, their custom-designed
molecule, Fentomycin-1 (Fento-1), reactivates this iron and initiates the
oxidative breakdown of phospholipids, leading to the death of targeted cancer
cells.
CD44 and iron: a toxic duo for cancer cells
A major finding of the study is the identification of a particularly
sensitive tumor subpopulation: CD44high cells. This surface marker,
linked to cancer stem cells and mesenchymal states, promotes iron endocytosis.
As a result, these cells accumulate redox-active iron in lysosomes, making them
especially vulnerable to ferroptosis induction by Fento-1.
In human samples of pancreatic cancer and sarcomas, Fento-1 selectively
reduced the CD44high population—even after exposure to standard
chemotherapies. The remaining cells adopted a more epithelial phenotype, with
lower iron content and thus increased resistance to ferroptosis, illustrating
adaptive cellular plasticity.
Impressive preclinical results
- In vitro: Fento-1 induces massive membrane
phospholipid oxidation in several human cancer lines (PDAC, sarcomas,
triple-negative breast cancer), with 2–3× greater efficacy than classical
ferroptosis inducers like RSL3 or erastin. In HT-1080 cells, Fento-1
rapidly increases 4-HNE (a lipid peroxidation marker) and boosts
lysophospholipid levels (2× to 5× depending on the species) within 24
hours.
- Ex vivo: In freshly dissociated tumor cells from
13 patients with pancreatic cancer or sarcoma, Fento-1 reduces the CD44high
population by ~50% in 24 hours (p < 0.01). This reduction correlates
with a significant rise in oxidized lipids (e.g., PCOx36:2, PCOx38:4),
averaging 2.5× higher than controls—an effect nullified by liproxstatin-1
or α-tocopherol co-treatment.
- In vivo: In a mouse model of metastatic
triple-negative breast cancer (4T1), intralymphatic administration of
Fento-1 (3 µg every other day for 15 days) led to a >60% reduction in
lymph node tumor volume by day 10 (p = 1.7 × 10⁻⁶), and significantly
improved survival (median extended from 20 to 28 days, p = 0.029). The
proportion of CD44high cells dropped from ~50% to <15% (p
< 0.01), with no change in animal weight—indicating good
tolerance.
Changing the paradigm: targeting iron, not the genome
This study proposes a paradigm shift in the fight against
treatment-resistant cancers. Instead of targeting oncogenic mutations, the
strategy leverages a transient metabolic state—lysosomal iron overload. This
cellular profile is associated with a mesenchymal state, high plasticity, and
resistance to traditional cytotoxic treatments.
Fento-1 could potentially eradicate
drug-tolerant persister cells (DTPs)
before they re-emerge, or enhance the efficacy of baseline treatments. The
researchers also propose using CD44 or iron load as biomarkers to guide the use
of such compounds in a precision medicine approach.
Read next: Ferroptosis: A Key Mechanism in Anti-Androgen Treatments for Prostate Cancer
A promising yet cautious therapeutic pathway
While the results are promising, challenges remain. The effects of
Fento-1 on non-tumoral iron-rich tissues are still unknown. Additionally,
cellular adaptation to ferroptotic stress suggests that intermittent or
combination therapies may be necessary to prevent resistance. A deeper
understanding of cell states favoring ferroptosis (e.g., mesenchymal, CD44high,
high oxidative stress) will be critical to optimizing this approach.
To conclude, this study positions lysosomal iron as a novel therapeutic
lever to target resistant solid tumors. Fento-1 operates at the crossroads of
redox biology and targeted pharmacology, exploiting an intrinsic metabolic
weakness. Translating this concept into the clinic will require identifying
ideal targets, therapeutic windows, and the most effective combinations.
Read next: Oncology: When AI Takes Control…
